GlassScriptPhysician profile
Richard Goyer
NPI 1558325043
$6,175.74
in general payments reported to CMS, 2019-2025
23 companies · $53.41 in 2025
The $53.41 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $522 · 2021: $713 · 2022: $3,397 · 2023: $889 · 2024: $78.91 · 2025: $53.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $2,140.00 | 2022 | |
| Abbvie INC. | $1,130.82 | 2019-2023 | |
| Hologic Sales and Service, LLC | $660.89 | 2019-2025 | Novasure, Acessa Provu System, Omni Hysteroscope |
| Mayne Pharma Commercial LLC | $292.71 | 2021-2023 | |
| Bausch Health US, LLC | $250.15 | 2020-2024 | Aplenzin, Wellbutrin |
| Novo Nordisk INC | $246.49 | 2019-2023 | Wegovy |
| Therapeuticsmd, INC. | $184.08 | 2019-2022 | |
| Myovant Sciences INC. | $168.47 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $142.87 | 2023 | Myfembree |
| Allergan, INC. | $136.30 | 2020 | |
| Pfizer INC. | $135.60 | 2019-2023 | |
| Coopersurgical, INC. | $97.40 | 2019 | |
| Avion Pharmaceuticals | $96.38 | 2019-2022 | |
| Medical Device Business Services, INC. | $95.39 | 2019 | |
| Exeltis, USA INC. | $90.34 | 2019-2023 | Slynd, Tyblume |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $87.46 | 2022-2023 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $60.13 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $44.47 | 2021-2024 | Zepbound |
| Lupin INC. | $41.28 | 2019 | |
| Merck Sharp & Dohme LLC | $28.49 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.16 | 2022 | |
| Millicent US INC | $14.25 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Goyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.